What Happened
Scientists have developed a new DNA testing approach that can diagnose rare genetic diseases that standard genetic tests routinely miss, according to research published this week. The breakthrough addresses a critical gap in modern medicine: while standard genetic sequencing can identify common disease-causing mutations, millions of patients with rare diseases remain undiagnosed because their genetic variants are too unusual or complex for conventional tests to detect.
How the New Test Works
The new test uses long-read sequencing technology, which reads much longer segments of DNA than traditional short-read sequencing. Standard genetic tests break DNA into small fragments of 150-300 base pairs before reading them, which can miss structural variants — large rearrangements, deletions, duplications, or inversions of genetic material — that are common causes of rare diseases. The new approach reads DNA fragments up to 100,000 base pairs long, allowing it to detect these structural variants with far greater accuracy.
In a validation study involving 250 patients with suspected rare genetic diseases who had previously received negative results from standard genetic testing, the new approach identified causative genetic variants in 35% of cases. For patients who had been searching for answers for years — some for over a decade — the diagnosis provided not just closure but often led to changes in clinical management, including targeted therapies and participation in clinical trials.
Impact on Rare Disease Patients
Rare diseases affect an estimated 300 million people worldwide, yet approximately 50% of patients remain undiagnosed after standard genetic testing. Each year, patients and families spend an average of $50,000 on diagnostic odysseys — the long and costly journey to find a diagnosis. The new test could dramatically reduce this burden. For children with severe developmental delays, metabolic disorders, or neurological conditions, getting a genetic diagnosis can be life-changing, enabling access to specialized care, family planning information, and in some cases, targeted gene therapies.
India Angle
India has a particularly high burden of rare genetic diseases due to its large population, high rate of consanguineous marriage in certain communities, and limited newborn screening programs. Estimates suggest over 70 million Indians may be affected by rare diseases, with many going undiagnosed due to limited access to advanced genetic testing. The high cost of genetic testing — typically Rs 50,000 to Rs 2 lakh for standard panels — and the concentration of genetic specialists in major cities have created significant diagnostic disparities.
The new long-read sequencing approach, while currently more expensive than standard testing, is expected to become more affordable as the technology scales. Indian companies like Strand Life Sciences, MedGenome, and MapMyGenome are already leaders in genetic testing and could adopt this technology for the Indian market. The Indian government's National Policy for Rare Diseases 2021 provides a framework for diagnosis and treatment, but the policy has been criticized for its limited budget and reach. This diagnostic breakthrough could make the policy more effective by identifying more patients who can benefit from existing treatments and clinical trials.
Sources
• SciTechDaily: New DNA Test Solves Rare Disease Mysteries
• ScienceDaily: Rare disease diagnostics breakthrough
• Cell: Original research publication
Internal Links
• Medical breakthroughs in chronic disease
• Scientific discoveries that change our understanding
